Literature DB >> 27080087

In silico methods for drug repurposing and pharmacology.

Rachel A Hodos1,2, Brian A Kidd1, Khader Shameer1, Ben P Readhead1, Joel T Dudley1.   

Abstract

Data in the biological, chemical, and clinical domains are accumulating at ever-increasing rates and have the potential to accelerate and inform drug development in new ways. Challenges and opportunities now lie in developing analytic tools to transform these often complex and heterogeneous data into testable hypotheses and actionable insights. This is the aim of computational pharmacology, which uses in silico techniques to better understand and predict how drugs affect biological systems, which can in turn improve clinical use, avoid unwanted side effects, and guide selection and development of better treatments. One exciting application of computational pharmacology is drug repurposing-finding new uses for existing drugs. Already yielding many promising candidates, this strategy has the potential to improve the efficiency of the drug development process and reach patient populations with previously unmet needs such as those with rare diseases. While current techniques in computational pharmacology and drug repurposing often focus on just a single data modality such as gene expression or drug-target interactions, we argue that methods such as matrix factorization that can integrate data within and across diverse data types have the potential to improve predictive performance and provide a fuller picture of a drug's pharmacological action. WIREs Syst Biol Med 2016, 8:186-210. doi: 10.1002/wsbm.1337 For further resources related to this article, please visit the WIREs website.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27080087      PMCID: PMC4845762          DOI: 10.1002/wsbm.1337

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Syst Biol Med        ISSN: 1939-005X


  141 in total

Review 1.  A comparative study of European rare disease and orphan drug markets.

Authors:  Alain Denis; Lut Mergaert; Christel Fostier; Irina Cleemput; Steven Simoens
Journal:  Health Policy       Date:  2010-06-17       Impact factor: 2.980

2.  An integrative genomics approach to infer causal associations between gene expression and disease.

Authors:  Eric E Schadt; John Lamb; Xia Yang; Jun Zhu; Steve Edwards; Debraj Guhathakurta; Solveig K Sieberts; Stephanie Monks; Marc Reitman; Chunsheng Zhang; Pek Yee Lum; Amy Leonardson; Rolf Thieringer; Joseph M Metzger; Liming Yang; John Castle; Haoyuan Zhu; Shera F Kash; Thomas A Drake; Alan Sachs; Aldons J Lusis
Journal:  Nat Genet       Date:  2005-06-19       Impact factor: 38.330

3.  Global mapping of pharmacological space.

Authors:  Gaia V Paolini; Richard H B Shapland; Willem P van Hoorn; Jonathan S Mason; Andrew L Hopkins
Journal:  Nat Biotechnol       Date:  2006-07       Impact factor: 54.908

Review 4.  Cheminformatics at the interface of medicinal chemistry and proteomics.

Authors:  Uwe Koch; Michael Hamacher; Peter Nussbaumer
Journal:  Biochim Biophys Acta       Date:  2013-05-21

5.  Scale-free networks: a decade and beyond.

Authors:  Albert-László Barabási
Journal:  Science       Date:  2009-07-24       Impact factor: 47.728

Review 6.  The productivity crisis in pharmaceutical R&D.

Authors:  Fabio Pammolli; Laura Magazzini; Massimo Riccaboni
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

7.  Cancer as the Disintegration of Robustness: Population-Level Variance in Gene Expression Identifies Key Differences Between Tobacco- and HPV-Associated Oropharyngeal Carcinogenesis.

Authors:  Miriam M Ben-Dayan; Thomas MacCarthy; Nicolas F Schlecht; Thomas J Belbin; Geoffrey Childs; Richard V Smith; Michael B Prystowsky; Aviv Bergman
Journal:  Arch Pathol Lab Med       Date:  2015-07-01       Impact factor: 5.534

Review 8.  Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience.

Authors:  L Ferry; J A Johnston
Journal:  Int J Clin Pract       Date:  2003-04       Impact factor: 2.503

9.  Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease.

Authors:  Arvind K Chavali; Anna S Blazier; Jose L Tlaxca; Paul A Jensen; Richard D Pearson; Jason A Papin
Journal:  BMC Syst Biol       Date:  2012-04-27

10.  From genomics to chemical genomics: new developments in KEGG.

Authors:  Minoru Kanehisa; Susumu Goto; Masahiro Hattori; Kiyoko F Aoki-Kinoshita; Masumi Itoh; Shuichi Kawashima; Toshiaki Katayama; Michihiro Araki; Mika Hirakawa
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

View more
  81 in total

1.  Validation strategies for target prediction methods.

Authors:  Neann Mathai; Ya Chen; Johannes Kirchmair
Journal:  Brief Bioinform       Date:  2020-05-21       Impact factor: 11.622

2.  Leveraging Big Data to Transform Drug Discovery.

Authors:  Benjamin S Glicksberg; Li Li; Rong Chen; Joel Dudley; Bin Chen
Journal:  Methods Mol Biol       Date:  2019

Review 3.  Insights into Computational Drug Repurposing for Neurodegenerative Disease.

Authors:  Manish D Paranjpe; Alice Taubes; Marina Sirota
Journal:  Trends Pharmacol Sci       Date:  2019-07-17       Impact factor: 14.819

4.  Integrative Analysis of Disease Signatures Shows Inflammation Disrupts Juvenile Experience-Dependent Cortical Plasticity.

Authors:  Milo R Smith; Poromendro Burman; Masato Sadahiro; Brian A Kidd; Joel T Dudley; Hirofumi Morishita
Journal:  eNeuro       Date:  2017-01-18

5.  Machine Learning for Integrating Data in Biology and Medicine: Principles, Practice, and Opportunities.

Authors:  Marinka Zitnik; Francis Nguyen; Bo Wang; Jure Leskovec; Anna Goldenberg; Michael M Hoffman
Journal:  Inf Fusion       Date:  2018-09-21       Impact factor: 12.975

6.  Harnessing Human Microphysiology Systems as Key Experimental Models for Quantitative Systems Pharmacology.

Authors:  D Lansing Taylor; Albert Gough; Mark E Schurdak; Lawrence Vernetti; Chakra S Chennubhotla; Daniel Lefever; Fen Pei; James R Faeder; Timothy R Lezon; Andrew M Stern; Ivet Bahar
Journal:  Handb Exp Pharmacol       Date:  2019

7.  Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs.

Authors:  Dominique Douguet
Journal:  ACS Med Chem Lett       Date:  2018-01-29       Impact factor: 4.345

8.  DR2DI: a powerful computational tool for predicting novel drug-disease associations.

Authors:  Lu Lu; Hua Yu
Journal:  J Comput Aided Mol Des       Date:  2018-04-23       Impact factor: 3.686

9.  Sepsis in the era of data-driven medicine: personalizing risks, diagnoses, treatments and prognoses.

Authors:  Andrew C Liu; Krishna Patel; Ramya Dhatri Vunikili; Kipp W Johnson; Fahad Abdu; Shivani Kamath Belman; Benjamin S Glicksberg; Pratyush Tandale; Roberto Fontanez; Oommen K Mathew; Andrew Kasarskis; Priyabrata Mukherjee; Lakshminarayanan Subramanian; Joel T Dudley; Khader Shameer
Journal:  Brief Bioinform       Date:  2020-07-15       Impact factor: 11.622

10.  HSP90 inhibitor geldanamycin reverts IL-13- and IL-17-induced airway goblet cell metaplasia.

Authors:  Alejandro A Pezzulo; Rosarie A Tudas; Carley G Stewart; Luis G Vargas Buonfiglio; Brian D Lindsay; Peter J Taft; Nicholas D Gansemer; Joseph Zabner
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.